The FDA Black Box Warning Controversy and Recent Updates: What Every Woman Should Know About Hormone Therapy

For over two decades, a black box warning on hormone therapy products has shaped—and limited—menopause care for millions of women. In November 2025, the FDA announced the removal of these warnings, marking a historic shift in women's health policy. But what exactly happened? Why were these warnings placed in the first place, what made them controversial, and what does their removal mean for you?

The 2002 Study That Changed Everything

To understand the controversy, we need to go back to July 2002, when the Women's Health Initiative (WHI) made headlines around the world. This massive, government-funded study was stopped early after researchers reported alarming findings: hormone replacement therapy appeared to increase the risk of breast cancer, heart disease, stroke, and blood clots.

The media coverage was immediate and dramatic. Women who had been taking hormones for years were suddenly fearful. Many stopped their medications overnight. Doctors, concerned about liability and patient safety, largely stopped prescribing hormone therapy altogether.

The numbers tell the story: hormone therapy use among postmenopausal women plummeted from about 27% in 1999 to just 5% by 2020. An entire generation of women went through menopause with limited treatment options, often suffering with debilitating symptoms.

Shortly after the WHI results were published, the FDA implemented black box warnings—the agency's strongest available measure short of removing a drug from the market—on all menopause treatments containing estrogen. These warnings cautioned about risks of cardiovascular disease, breast cancer, stroke, blood clots, and dementia.

What Was the Women's Health Initiative?

The WHI was launched in 1991 as one of the largest women's health research projects ever undertaken in the United States. It enrolled more than 161,000 postmenopausal women between ages 50 and 79, with the goal of studying ways to prevent the leading causes of death and disability in older women.

The hormone therapy component tested two specific regimens:

• Women with a uterus received Prempro (conjugated equine estrogen plus medroxyprogesterone acetate)
• Women who had undergone hysterectomy received Premarin (conjugated equine estrogen) alone

The study's primary aim was to determine whether hormone therapy could prevent heart disease and other chronic conditions. It was not designed to assess effectiveness for treating menopausal symptoms like hot flashes or night sweats—ironically, the very reason most women take hormone therapy.

The Critical Flaws in the WHI Study

As researchers conducted follow-up analyses over the subsequent years, several major problems with the original WHI study became apparent:

1. The Wrong Age Group

The average age of participants was 63 years old—more than a decade past the typical age of menopause (around 51). Only 30% of participants were under age 60, meaning the majority were ages 60-79.

This matters enormously because these older women were well past the "critical window" for starting hormone therapy. Many already had existing cardiovascular issues or vascular damage from years without estrogen. Starting hormone therapy so long after menopause may have actually destabilized existing arterial plaque rather than providing protection.

When researchers later analyzed the data by age group, they found dramatically different results. Women who started hormone therapy in their 50s or within 10 years of menopause showed cardiovascular benefits and reduced mortality—exactly the opposite of what had been reported for the older age groups.

2. The Wrong Formulations

The WHI used only one specific formulation: oral conjugated equine estrogen (derived from pregnant mare urine) combined with medroxyprogesterone acetate, a synthetic progestin. This is not the same as the bioidentical hormones or transdermal preparations commonly used today.

Oral estrogen undergoes "first pass" metabolism through the liver, which increases production of clotting factors. This explains the increased incidence of blood clots and stroke seen in the study. Modern transdermal estrogen (patches, gels, creams) bypasses the liver and does not have this same effect on clotting factors.

Additionally, the specific progestin used in the study—medroxyprogesterone acetate—is now understood to carry higher risks than other progestins or bioidentical progesterone. Most experts believe the increased breast cancer risk was linked primarily to this specific progestin, not to estrogen itself. In fact, the estrogen-only arm of the study actually showed a decrease in breast cancer risk.

3. Misleading Risk Communication

One of the most problematic aspects of the WHI was how the risks were communicated. The study emphasized relative risk rather than absolute risk, which made the dangers seem far more alarming than they actually were.

For example, the study reported a "29% increase in coronary heart disease" with hormone therapy. This is a relative risk figure. The absolute risk was far smaller: out of 10,000 women, there were only 7 additional cardiac events per year. Similarly, there were 8 additional breast cancers per 10,000 women per year—an absolute increase of 0.08%.

When presented with only the relative risk, many women and doctors concluded that hormone therapy was extremely dangerous. But the absolute risks were actually quite small, especially when weighed against the benefits for symptom relief and quality of life.

4. Study Design Issues

Several investigators have pointed out that the WHI didn't even meet the criteria for a proper randomized controlled trial:

• After randomization, women were free to stop their assigned treatment
• The rate of "unblinding" was 45% in the hormone group, meaning nearly half knew what they were taking
• Multiple warnings about increased risks were sent to participants during the study, which could have influenced their health behaviors and outcomes

The Real-World Consequences

The fallout from the WHI was devastating for women's health. An estimated 91,000 postmenopausal women in the U.S. died prematurely between 2002 and 2012 from conditions that hormone therapy might have helped prevent.

Women who could have safely benefited from hormone therapy—particularly those with severe symptoms in their 50s—were denied treatment. Many endured years of hot flashes, night sweats, insomnia, vaginal atrophy, and accelerated bone loss.

The study also had downstream effects on other health outcomes:

• Endometrial cancer rates increased after hormone therapy use declined
• Osteoporotic fracture rates rose
• Many women experienced reduced quality of life, impacts on work performance, and relationship difficulties

Perhaps most troubling, the black box warning was applied across the board to all hormone products, including low-dose vaginal estrogen—which is minimally absorbed systemically and carries virtually no cardiovascular or breast cancer risk. This left even women with severe vaginal atrophy without appropriate treatment options.

The Mounting Evidence for Hormone Therapy

Over the past 20 years, a substantial body of research has accumulated showing that for the right women at the right time, hormone therapy is both safe and beneficial:

The Timing Hypothesis

One of the most important concepts to emerge is the "critical window" or "timing hypothesis." Research consistently shows that when hormone therapy is initiated within 10 years of menopause or before age 60, women experience:

• 48-50% reduction in fatal heart attacks
• 30% reduction in all-cause mortality
• 35% reduction in Alzheimer's disease risk
• 50-60% reduction in bone fractures
• Reduced risk of type 2 diabetes
• Improved cognitive function and quality of life

The key insight is that estrogen helps maintain healthy, flexible blood vessels. When there's continuous estrogen exposure—either from ovaries or from hormone therapy—blood vessels stay soft and resilient. But after more than 10 years without estrogen, vessels begin to harden and develop plaque. Starting hormone therapy after this extended gap can potentially destabilize existing plaque, which explains the cardiovascular risks seen in the older WHI participants.

Formulation Matters

Modern hormone therapy looks very different from what was tested in the WHI:

• Transdermal estrogen (patches, gels, sprays) has a more favorable risk profile than oral estrogen
• Bioidentical progesterone or newer progestins appear safer than medroxyprogesterone acetate
• Lower doses are now standard practice
• Individualized regimens can be tailored to each woman's needs and risk factors

The Benefits Are Real

Hormone therapy remains the most effective treatment for:

• Vasomotor symptoms (hot flashes and night sweats)
• Genitourinary syndrome of menopause (vaginal dryness, painful intercourse, urinary symptoms)
• Sleep disturbances related to menopause
• Prevention of bone loss and osteoporotic fractures

For women with early or surgical menopause (before age 45), hormone therapy until at least age 50 is considered standard care to prevent long-term health consequences of premature estrogen loss.

The Historic FDA Decision: November 2025

On November 10, 2025, the FDA announced it would remove black box warnings from hormone therapy products. This decision followed:

• A comprehensive review of the scientific literature
• An expert panel convened in July 2025
• A 60-day public comment period
• Extensive deliberation about the implications for women's health

What's Changing

The FDA is working with pharmaceutical companies to:

• Remove black box warnings from all estrogen-containing products (systemic and vaginal)
• Update product labeling to reflect current evidence
• Remove references to risks of cardiovascular disease, breast cancer, and dementia (except for endometrial cancer risk with unopposed estrogen)
• Eliminate the mandate to prescribe "the lowest effective dose for the shortest duration"
• Include guidance on optimal timing: starting within 10 years of menopause or before age 60

The FDA also approved two new products:

• The first generic version of Premarin in over 30 years, improving affordability and access
• A new non-hormonal treatment for moderate to severe hot flashes, providing options for women who cannot or choose not to use hormones

The FDA's Rationale

FDA Commissioner Marty Makary stated that millions of women have been denied the potential health benefits of hormone therapy due to "distorted" risk factors. HHS Secretary Robert F. Kennedy Jr. called it a return to "evidence-based medicine" and giving women "control over their health again."

The agency acknowledged that for more than two decades, fear and misinformation surrounding hormone therapy had resulted in women and physicians having an incomplete view of the treatment. The removal of the black box warning aims to restore confidence in hormone therapy while ensuring that prescribing decisions are based on current science rather than outdated fears.

Expert Perspectives: Cause for Celebration—and Caution

The medical community has had mixed reactions to the FDA's decision.

Support for the Change

The American College of Obstetricians and Gynecologists (ACOG) and many menopause specialists welcomed the removal of the black box warning. They argue that:

• The warning created unnecessary fear that prevented appropriate treatment
• Vaginal estrogen especially should never have carried such severe warnings
• The change lowers barriers to appropriate care
• It reflects the evolving scientific evidence
• Women deserve accurate information to make informed decisions

The European Menopause and Andropause Society (EMAS) also welcomed the decision, calling it "more than a regulatory correction—it is an acknowledgement of a structural gap in women's health."

Concerns About Overcorrection

However, some experts worry that the pendulum may have swung too far in the opposite direction. Dr. Susan Loeb-Zeitlin from Weill Cornell Medicine noted that while the removal of black box warnings from vaginal estrogen was expected and appropriate, removing them from all systemic hormone therapy formulations may give women the impression that hormone therapy is universally safe and appropriate.

Critics point out that:

• Hormone therapy is not right for every woman
• Individual risk assessment is still essential
• Some women have contraindications (history of breast cancer, blood clots, stroke, heart disease)
• Benefits must be weighed against risks for each person
• The goal should be appropriate prescribing, not maximal prescribing

There's concern that after decades of undertreating menopausal symptoms, we could swing to indiscriminate prescribing without proper individualized evaluation.

What This Means for You: A Balanced Perspective

The removal of the black box warning is significant, but it doesn't mean hormone therapy is automatically right for every woman in menopause. Here's what you need to know:

You're a Good Candidate for Hormone Therapy If:

• You're experiencing bothersome menopausal symptoms (hot flashes, night sweats, sleep disruption)
• You're under 60 or within 10 years of your final menstrual period
• You don't have contraindications (history of breast cancer, blood clots, stroke, unexplained vaginal bleeding, active liver disease)
• You're interested in preventing bone loss if you're at increased risk for osteoporosis
• You have genitourinary syndrome of menopause (vaginal dryness, painful sex, urinary symptoms)

Vaginal Estrogen Is Different

Low-dose vaginal estrogen for treating vaginal atrophy is the safest form of hormone therapy. It works locally with minimal systemic absorption and can be used by most women, including many breast cancer survivors. If your only symptoms are vaginal or urinary, this is typically the preferred treatment.

Timing Is Everything

If you're in your 50s or within 10 years of menopause, you're in the optimal window for starting hormone therapy if you need it. If you're over 60 or more than 10 years past menopause, hormone therapy can still be considered but requires more careful evaluation of cardiovascular risk.

Modern Formulations Are Preferred

When starting hormone therapy today, most experts recommend:

• Transdermal estrogen (patch, gel, spray) rather than oral
• Bioidentical progesterone or newer progestins for women with a uterus
• The lowest effective dose for symptom control (not necessarily the absolute lowest dose)
• Regular reassessment of whether continued use is appropriate

Individual Assessment Is Key

Despite the removal of the black box warning, hormone therapy is not a one-size-fits-all solution. Your healthcare provider should:

• Take a detailed personal and family medical history
• Assess your cardiovascular risk factors
• Discuss your specific symptoms and treatment goals
• Explain the benefits and risks based on your individual situation
• Support you in making an informed decision
• Monitor you regularly if you start treatment

Hormone Therapy Isn't the Only Option

For women who can't or don't want to use hormone therapy, other options exist:

• Non-hormonal FDA-approved medications for hot flashes (like fezolinetant)
• SSRIs or SNRIs in low doses
• Gabapentin or pregabalin
• Cognitive behavioral therapy for insomnia and hot flashes
• Lifestyle modifications (cooling strategies, stress reduction, exercise, healthy diet)
• Vaginal moisturizers and lubricants for vaginal symptoms

The Bigger Picture

The black box warning saga highlights broader issues in women's health:

Underrepresentation in Research

Women—particularly older women—have historically been underrepresented in medical research. The WHI itself had significant limitations but was still one of the most comprehensive studies of postmenopausal women's health.

Medical Education Gaps

Menopause is insufficiently taught in medical school and residency training. Many physicians lack confidence in prescribing hormone therapy or counseling women about menopause.

The "Medicalization" Debate

For decades, there's been tension between viewing menopause as a natural life transition versus a hormone deficiency requiring treatment. The truth is more nuanced: menopause is a natural process, but the symptoms can be severe and the long-term health consequences of estrogen loss are real. Women deserve access to treatments that can improve their quality of life and long-term health.

The dramatic reduction in hormone therapy prescribing after 2002 meant that an entire generation of women suffered unnecessarily. 

Moving Forward: What Needs to Happen

The removal of the black box warning is an important step, but more work is needed:

1. Provider Education: Healthcare professionals need updated training on modern hormone therapy prescribing
2. Patient Education: Women need accurate, balanced information to make informed decisions
3. Continued Research: We need more studies on long-term outcomes, diverse populations, and optimal treatment regimens
4. Access and Affordability: Generic options and insurance coverage need to improve
5. Individualized Care: The focus should shift from blanket recommendations to personalized risk-benefit assessments

The Bottom Line

The FDA's removal of black box warnings on hormone therapy represents a long-overdue correction based on 20+ years of accumulated evidence. For most women in their 50s with bothersome menopausal symptoms, hormone therapy is safe and effective when prescribed appropriately.

However, this isn't permission to prescribe—or take—hormones indiscriminately. The goal is thoughtful, individualized care that considers each woman's unique circumstances, symptoms, risk factors, and preferences.

If you're experiencing menopausal symptoms, this is a good time to have an informed conversation with a healthcare provider who is knowledgeable about menopause. Whether or not you decide to use hormone therapy, you deserve to have all the options explained clearly so you can make the best decision for your health and quality of life.

The tragedy of the past two decades wasn't just the flawed study—it was the failure to provide women with nuanced, evidence-based guidance. As we move forward, let's ensure that women have access to accurate information, appropriate treatment options, and compassionate, expert care during this important life stage.